Real-world experience from the UK


A retrospective review of adult patients with moderate-to-severe AD following treatment with DUPIXENT2

NEWCASTLE: 100 patients, review at 8–16 weeks following DUPIXENT2

  • Proportion of patients achieving EASI-50, EASI-75 and EASI-90 at Week 16*†2

    At 16 weeks, 84%, 61% and 35% of patients on DUPIXENT achieved EASI-50, EASI-75 and EASI-90 respectively2

      A retrospective 10-month review of 100 patients between June and August 2020. Outcomes were recorded between 8–16 weeks following treatment with DUPIXENT. The study focused on patient population reimbursed by the National Institute for Health and Care Excellence.2 97% of patients (N=100) received at least one systemic medication prior to DUPIXENT. The proportion of these 97 patients that received one, two, three or four prior treatments was 30%, 33%, 33% and 4% respectively. Prior medications included methotrexate (61%), ciclosporin (22%), azathioprine (16%) and alitretinoin (1%).2

  • Mean EASI score at baseline and review checkpoints*†2

    At Week 16 the mean EASI score was 5.8 compared to 22.2 at baseline in patients on DUPIXENT2

      A retrospective 10-month review of 100 patients between June and August 2020. Outcomes were recorded between 8–16 weeks following treatment with DUPIXENT. The study focused on patient population reimbursed by the National Institute for Health and Care Excellence.2 97% of patients (N=100) received at least one systemic medication prior to DUPIXENT. The proportion of these 97 patients that received one, two, three or four prior treatments was 30%, 33%, 33% and 4% respectively. Prior medications included methotrexate (61%), ciclosporin (22%), azathioprine (16%) and alitretinoin (1%).2

  • Mean DLQI score at baseline and review checkpoints‡2

    At Week 16 the mean DLQI score was 3.7 compared to 17.5 at baseline in patients on DUPIXENT2

      A retrospective 10-month review of 100 patients between June and August 2020. Outcomes were recorded between 8–16 weeks following treatment with DUPIXENT. The study focused on patient population reimbursed by the National Institute for Health and Care Excellence.2 97% of patients (N=100) received at least one systemic medication prior to DUPIXENT. The proportion of these 97 patients that received one, two, three or four prior treatments was 30%, 33%, 33% and 4% respectively. Prior medications included methotrexate (61%), ciclosporin (22%), azathioprine (16%) and alitretinoin (1%).2

  • Mean POEM score at baseline and review checkpoints§2

    At Week 16 the mean POEM score was 7.1 compared to 22.5 at baseline in patients on DUPIXENT2

      A retrospective 10-month review of 100 patients between June and August 2020. Outcomes were recorded between 8–16 weeks following treatment with DUPIXENT. The study focused on patient population reimbursed by the National Institute for Health and Care Excellence.2 97% of patients (N=100) received at least one systemic medication prior to DUPIXENT. The proportion of these 97 patients that received one, two, three or four prior treatments was 30%, 33%, 33% and 4% respectively. Prior medications included methotrexate (61%), ciclosporin (22%), azathioprine (16%) and alitretinoin (1%).2

Baseline characteristics


 

NEWCASTLE2
(N=100)

Median age (years)

41

Mean (SE) EASI

22.2 (1.2)

Mean (SE) DLQI

17.5 (0.7)

Mean (SE) POEM

22.5 (0.5)

DUPIXENT safety profile in the Newcastle study3


75 patients had response data recorded between 8–16 weeks, 18 had stopped DUPIXENT treatment and 7 had missing data¶3


Efficacy

Want to know how DUPIXENT can help your patients? Find out more about the Phase 3 clinical trials of DUPIXENT.




Find out more


Safety Profile

Learn more about safety profile of DUPIXENT.






Find out more


Dosing

Learn more about how to administer DUPIXENT.






Find out more

    *An EASI score is based on a clinician’s weighted score (0 to 72) of four affected areas grading the physical signs of AD (erythema, oedema/papulation, excoriation, lichenification).4–8
    The target time for EASI response assessment was 16 weeks, but outcome data recorded between 8 and 16 weeks was included, using the score nearest to 16 weeks where multiple scores were available.2
    The DLQI score is based on a 10-item patient questionnaire that assesses six different aspects that may affect quality of life. These aspects are symptoms and feelings, daily activities, leisure, work and school performance, personal relationships, and treatment. Each question is scored from 0 (not at all) to 3 (very much) and then totalled for the final score.4,5
    §
    The POEM score is based on scores from seven items each assessed on a five-point scale. The maximum score is 28 and higher scores indicate a poorer quality of life.5
    Compared with prospective clinical trials, real-world data have the limitations of missing data and slight scoring date variations, including the impact of the COVID-19 pandemic on missed appointments. 16-week outcome data are not available for patients who withdrew from treatment. Reasons for withdrawal were mainly ophthalmic related, other reasons included recurrent infections, pregnancy, urticated rash, serum like sickness and lack of efficacy.2

    AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; POEM, patient-oriented eczema measure; SE, standard error; UK, United Kingdom.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Bajwa D, et al. Real-world response to dupilumab in patients with atopic dermatitis: a retrospective review of 100 patients. Abstract P81. Presented at the 101st British Association of Dermatologists Annual meeting, Virtual, July 6–8 2021.
    3. Bajwa D, et al. Real-world response to dupilumab in patients with atopic dermatitis: a retrospective review of 100 patients. Poster P81. Presented at the 101st British Association of Dermatologists Annual meeting, Virtual, July 6–8 2021.
    4. © NICE [2018] Dupilumab for treating moderate to severe atopic dermatitis. Available at: https://www.nice.org.uk/guidance/TA534/chapter/1-Recommendations. Date accessed: December 2021. All rights reserved. Subject to notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
    5. Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul. Appendix 5, Validity of Outcomes Measures. Available at: https://www.ncbi.nlm.nih.gov/books/NBK539234/. Date accessed: December 2021.
    6. EASI User Guide. HOME – Harmonising Outcome Measures for Eczema website. Available at: http://www.homeforeczema.org/documents/easi-user-guide-dec-2016-v2.pdf. Date accessed: December 2021.
    7. Leshem YA, et al. Br J Dermatol. 2015;172(5):1353–1357.
    8. Fattah D, et al. Chair’s presentation. Dupilumab for treating moderate to severe atopic dermatitis (ID1048) presented at the 2nd Appraisal Committee meeting lead team presentation, May 10 2018.

MAT-IE-2101031(v4.0) | Date of preparation: February 2022